好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Categorical change in T2 lesion volume and clinical outcomes in the phase III FREEDOMS and its extension study, evaluating fingolimod in patients with relapsing-remitting multiple sclerosis
Multiple Sclerosis
(-)
166
Authors/Disclosures
Douglas R. Jeffery, MD, PhD (Lake Norman Neurology At Piedmont Health Care)
PRESENTER
No disclosure on file
Claire E. Carrazco, DO (Emerson Hospital) No disclosure on file
Elisabetta Verdun Di Cantogno, MD (Merck Serono Int, SA) Dr. Verdun Di Cantogno has received personal compensation for serving as an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA. Dr. Verdun Di Cantogno has stock in EMD Serono Research & Development Institute, Inc., Billerica, MA, USA.
No disclosure on file
No disclosure on file
Peter S. Chin, MD (Denali) No disclosure on file
William Camu, MD (Centre Gui de Chauliac) No disclosure on file